I am utilizing various methods to engineer superior T cells for cancer immunotherapy. These include designing chimeric receptors, altering signaling networks, and introducing mutations. Hopefully these engineered T cells will be able to preferentially expand in vivo, overcome the hostile tumor microenvironment and produce a better therapeutic option for patients. I also manage the flow cytometry core for the Deeley Research Centre, where we have recently acquired two Cytek Aurora instruments and a BD FACS Melody sorter.

Back to top